Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects
- 1.2k Downloads
To assess the potential of dexmedetomidine for targeted sedation in complex Intensive Care (ICU) patients for >24 h.
Prospective, open label, clinical trial.
Tertiary general ICU.
Twenty critically ill patients, mean APACHE II 23(±9).
A continuous infusion of dexmedetomidine, median infusion time 71.5 (35–168) h, starting at 0.4μg·kg·h without a loading dose and adjusted (0.2–0.7μg·kg·h) to a target Ramsay Sedation Score (RSS) of 2–4. Rescue midazolam and/or morphine/fentanyl were given as clinically indicated.
Measurements and results
Haemodynamic parameters and RSSs were collected until 24 h after cessation. An RSS 2–5 was achieved in 1,147 (83%) of observations with a reduction in RSS of 6 from 13% in the first 6 h to 3% between 18 h and 24 h. Sixteen patients needed minimal or no additional midazolam, median 4 mg/day (0.5–10) and ten required minimal or no additional analgesia, median 2 mg/day (0.5–4.5), 55μg/day (14–63) of morphine/fentanyl.
A 16% reduction in mean systolic blood pressure (SBP) and 21% reduction in heart rate (HR) occurred over the first 4 h followed by minimal (± 10%) changes throughout the infusion. A rise in SBP was observed in two patients. After abrupt cessation, SBP and HR monitored for 24 h rose by 7% and 11%, respectively.
Dexmedetomidine was an effective sedative and analgesic sparing drug in critically ill patients when used without a loading dose for longer than 24 h with predictable falls in blood pressure and HR. There was no evidence of cardiovascular rebound 24 h after abrupt cessation of infusion.
KeywordsDexmedetomidine Sedatives Intensive care unit Analgesics
We thank David Bihari and the intensive care nursing staff for their contribution.
- 4.Triltsch AE, Welte M, von Homeyer P, Grosse J, Genahr A, Moshirzadeh M, Sidiropoulos A, Konertz W, Kox WJ, Spies CD (2002) Bispectral index-guided sedation with dexmedetomidine in intensive care: a prospective, randomized, double blind, placebo–controlled phase II study. Crit Care Med 30:1007–10014CrossRefPubMedGoogle Scholar
- 5.Venn RM, Bradshaw CJ, Spencer R, Brealey D, Caudwell E, Naughton C, Vedio A, Singer M, Feneck R, Treacher D, Willatts SM, Grounds RM (1999) Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia 54:1136–1142CrossRefPubMedGoogle Scholar
- 6.Venn RM, Hell J, Grounds RM (2000) Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care (London) 4:302–308Google Scholar
- 12.Cummings DM, Vlasses PH (1982) Antihypertensive drug withdrawal syndrome. Drug Intel Clin Pharm 16:817–8122Google Scholar
- 13.Geyskes GG, Boer P, Dorhout Mees EJ (1979) Clonidine withdrawal. Mechanism and frequency of rebound hypertension. Br J Clinical Pharmac 7:55–62Google Scholar